financetom
Business
financetom
/
Business
/
Year 2018 in review: Government makes National Pension Scheme sharper and better
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Year 2018 in review: Government makes National Pension Scheme sharper and better
Dec 26, 2018 8:58 AM

The National Pension System (NPS) is a formidable retirement tool, which was made even better in 2018. Here’s what changed:

Maturity proceeds become entirely tax-free; Annuity income continues to be taxed, for now

Then: At the time of maturity, subscribers could withdraw 60 percent of their money in a lump sum, but there the tax exemption was applicable only on the 40 percent and the remaining balance of 20 percent of the corpus was taxable.

Now: After attaining the age of 60, the tax exemption limit for lump sum withdrawal on exit has been extended to 60 percent. With this, the entire withdrawal at the time of maturity will now be exempt from income tax.

NPS Potentially to generate high returns

Then: You could invest up to 50 percent in equity. After that, there was no option to go beyond investing in equity.

Now: Under the active choice mode, the subscriber can now invest up to 75 percent equity. The new ruling came in effect from October 1, 2018.

Continue investing in NPS even after retirement

Then: To extend the age up to 70 years, the subscribers need to inform at least 15 days prior to attaining 60 years of age or superannuation.

Now: Extension of entry age can be obtained up to 180 days after attaining 60 years of age or superannuation.

Extension norms in doing partial withdrawals

Then: You could only withdraw 25 percent of the contributions after three years from the date of joining the system and a maximum of three times during the entire tenure of subscription in certain exigencies like health, marriage, house and education.

Now: Apart from partially withdrawing money from exigencies like health, marriage, house and education, you can also withdraw 25 percent of the contributions after three years from the date of joining the system and a maximum of three times during the entire tenure of subscription against skill development activity like startups, new ventures.

Contribution to NPS for central government employees raised to 14%

Then: The government contributed 10 percent of the basic salary of its employees as its contribution. This amount was tax exempt.

Now: The government will contribute a higher 14 percent of the basic salary of its employees as its contribution. However, the employee’s contribution will remain at 10 percent. The increased amount is also tax exempt.

Tax deduction benefit extended to Tier-II account

Then: No tax deduction benefit was allowed under the Tier-II account. You could invest any time and withdraw money anytime from Tier-II account. There was no lock-in period associated.

Now: The contribution made in Tier II account of NPS will have the same tax deduction benefits (up to Rs.1.5 lakh under section 80C of Income Tax Act) compared to other schemes like general provident fund (GPF), contributory provident fund (CPF), employees provident fund (EPF) and public provident fund (PPF).

However, to avail such tax deduction benefit, you need to invest money for a minimum lock-in period of 3 years. The benefit will be available to central government employees only.

Freedom to select pension fund manager and make asset allocation of their own

Then: The Central government employees did not get a choice to decide the investment ratio between equity and debt investments. Investments were done in a pre-fixed asset allocation with equity exposure of not more than 15%. They did not even have the choice of selecting private sector fund managers.

Now: Government employees will now get a choice to choose the asset class and make an investment in equity and debt as their need. They will also be allowed to select private pension fund managers.

Source: Moneycontrol

First Published:Dec 26, 2018 5:58 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Identiv Receives Final US Approval to Sell Security Card Business to Viaprotech
Identiv Receives Final US Approval to Sell Security Card Business to Viaprotech
Aug 19, 2024
08:25 AM EDT, 08/19/2024 (MT Newswires) -- Identiv ( INVE ) said Monday that it has received US regulatory approval to sell its security access card and reader operations to Turkey's Viaprotech for $145 million. The Committee on Foreign Investment in the US approved Identiv's ( INVE ) application on Aug. 15, the company said. The two companies expect the...
Market Chatter: Uber Drivers in Kenya Reject App's Lower Fares, Collaborate to Raise Rates
Market Chatter: Uber Drivers in Kenya Reject App's Lower Fares, Collaborate to Raise Rates
Aug 19, 2024
08:21 AM EDT, 08/19/2024 (MT Newswires) -- Uber Technologies ( UBER ) drivers in Kenya are ignoring fares computed by the ride-hailing app and charging their own higher rates, Reuters reported, citing drivers in Nairobi. Drivers for Uber ( UBER ) and other ride-hailing apps message potential passengers and propose higher prices than those generated by the companies, Reuters said....
Couche-Tard Confirming Friendly Proposal Sent to Seven & i Holdings
Couche-Tard Confirming Friendly Proposal Sent to Seven & i Holdings
Aug 19, 2024
08:25 AM EDT, 08/19/2024 (MT Newswires) -- Circle K operator Alimentation Couche-Tard Inc. ( ANCTF ) , a global player in convenience stores, confirmed Monday that it recently submitted a friendly, non-binding proposal to Seven & i Holdings Co., Ltd. The company in a statement said it is focused on reaching a mutually agreeable transaction that benefits both companies' customers,...
Monte Rosa Therapeutics Doses First Participants in MRT-6160 Autoimmune Study
Monte Rosa Therapeutics Doses First Participants in MRT-6160 Autoimmune Study
Aug 19, 2024
08:25 AM EDT, 08/19/2024 (MT Newswires) -- Monte Rosa Therapeutics ( GLUE ) said Monday it has dosed the first participants in a phase 1 trial evaluating MRT-6160, its experimental molecular glue degrader targeting VAV1 for autoimmune diseases. Initial results are due in Q1 2025, the company said. Monte Rosa said the study will assess the safety, pharmacokinetics, and target...
Copyright 2023-2026 - www.financetom.com All Rights Reserved